Regulation of the proteasome system, which is responsible for the generation of most MHC class I-bound peptides, occurs through the interaction of the 20S proteasome with several regulatory proteins. One of these is PI31, which acts in vitro as an inhibitor of proteasome activity. Here, we demonstrate that, rather than inhibiting proteasome function, PI31 acts as a selective modulator of the proteasome-mediated steps in MHC class I antigen processing. Overexpression of PI31 in mouse embryonic cells has no impact on proteasome-mediated proteolysis. Instead, PI31, which localizes at the nuclear envelope͞endoplasmic reticulum membrane, selectively interferes with the maturation of immunoproteasome precursor complexes. Consequently, overexpression of PI31 abrogates MHC class I presentation of an immunoproteasome-dependent cytotoxic T lymphocyte epitope and reduces the surface MHC class I levels on IFN-␥-treated mouse embryonic cells. Thus, PI31 represents a cellular regulator of proteasome formation and of proteasome-mediated antigen processing.
T
he proteasome system plays a central role in the degradation of intracellular proteins. Proteasomes remove abnormal proteins from the cytosol, play a role in transcription factor activation, in cell-cycle progression and, to an important extent, in the proteolytic processes involved in MHC class I antigen processing (1, 2) . Proteasomes are composed of a 20S catalytic core that is attached to regulatory complexes, the 19S complex and the proteasome activator PA28 (3, 4) . The 20S complex consists of four heptameric rings. The outer rings are occupied by ␣-subunits, which serve as interaction sites for the docking of regulatory particles. Enzymatic activity is mediated by three subunits that are located in the two inner proteasomal ␤-rings, ␤1͞␦, ␤2͞MC14, and ␤5͞MB1. These subunits enter the proteasome complex as proforms preceded by a prosequence, which is removed during maturation of the precursor complex into a functional 20S proteasome (5, 6) .
Whereas most of the functions exerted by proteasomes require proteolytic activity but no particular cleavage specificity, the liberation of MHC class I ligands from full-length antigens or shorter antigenic sequences demands a highly specific cleavage site usage (7) . To accomplish this, cells are equipped with three IFN-␥-inducible facultative catalytic proteasome subunits, ␤1-induced (i)͞LMP2, ␤2i͞MECL-1, and ␤5i͞LMP7, which are preferentially incorporated into newly assembled 20S complexes and thereby replace the three constitutive catalytic subunits (8) . Both constitutive proteasomes as well as ␤1i͞LMP2, ␤2i͞ MECL-1, and ␤5i͞LMP7-containing proteasomes, so-called immunoproteasomes, are capable of antigenic peptide production. However, because of an only partial overlap in cleavage specificities and frequencies of cleavage site usage, it seems that the set of peptides produced by immunoproteasomes differs quantitatively and qualitatively from the one produced by constitutive proteasomes (9, 10) . These processing differences can lead to an enhanced or reduced cytotoxic T lymphocyte (CTL) recognition of infected or tumor cells (11) (12) (13) (14) (15) (16) .
Binding of the 19S regulatory particle confers proteindegrading activity onto the 20S complex, which is essential for proteasomal functioning. PA28 attached to the other side of the 20S can modulate proteolytic cleavages. Although PA28 does not change the cleavage specificity of 20S, it influences both the quantity and the quality of the peptide repertoire displayed by MHC class I molecules on the cell surface (13, 17) .
Recently, the function of a previously described (18) inhibitor of proteasome activity, PI31, was further examined (19, 20) . These in vitro studies showed that both purified and recombinant PI31 diminished the enzymatic activity of purified 20S proteasomes. Recombinant PI31 was found to compete with the proteasome regulators PA28 (19) and 19S͞PA700 (20) for binding to 20S, indicating that PI31 binds the 20S ␣-rings and may function by hindering substrate access to the 20S catalytic channel. Because these studies raised the possibility that PI31 might modulate cellular proteasome activity, we investigated the effects of PI31 on proteasome functioning in intact cells.
Methods
Cell Lines and Transfectant Cells. Cells were cultured as described (11) . To establish (m)PI31 transfectant cells, the pSG5-(m)PI3 expression construct (19) was introduced into MEC or B8 cells by using calcium phosphate precipitation. Cells were placed into limiting dilution, and transfectant clones were selected with puromycin (Ad5E1 MEC, 2 g͞ml) or zeocin (MEC217, MECPA28, B8, 100 g͞ml).
CFSE Labeling. Cells were resuspended in 1 ml of PBS containing 5 M carboxy-fluorescein diacetate-succinimidyl ester (CFSE; Molecular Probes) and labeled for 60 s at room temperature. Labeled cells were washed with medium and analyzed immediately or placed at 37°C and analyzed at the time intervals specified in the figure legends. Fluorescence was measured with a FACScalibur and analyzed with a CELLQUEST application program (Becton Dickinson).
GFP Degradation. Ad5E1 MECs and PI31-transfectant clones were transfected with a Ub-R-GFP construct (21) and LLnL (50 M final concentration) was added after 24 h. Three and one-half hours later, cells were trypsinized and then incubated in medium containing cyclohexamid (40 g͞ml) and anisomycin (30 g͞ml) at 37°C. Samples were taken at different time points and analyzed by flow cytometry in PBA buffer (PBS͞0.5% BSA͞0.02% NaN3) containing LLnL, cycloheximide, and anisomycin.
IB␣ Degradation. Ad5E1 MECs and PI31-transfectant clones were resuspended in medium at a concentration of 2.5 ϫ 10 6 cells per ml. Samples of 200 l were incubated without or with 20 ng͞ml recombinant (rec) mouse tumor necrosis factor-␣ (mTNF␣) for 30 min at 37°C. Then, 1 ml of ice cold PBS was added, and the cells were pelleted and frozen in liquid nitrogen. IkB␣ degradation was examined by Western blot analysis.
Western Blot Analysis. Immunoblot analyses were performed as described (22) . For detection of ubiquitinylated proteins, samples of 4 ϫ 10 5 cells were incubated at the temperatures specified in the figure legends and then lysed in lysis buffer with 5 mM NEM. Extracted proteins were separated on 9% polyacrylamide gels and transferred to nitrocellulose. Membranes were probed with FK1 mouse mAb, specific for polyubiquitin-linked proteins (Affiniti, U.K.). To analyze subunit composition of proteasome precursor and 20S complexes, pellets of 4 ϫ 10 8 cells were lysed in 1 ml of lysis buffer and applied to 10-40% glycerol gradients (13) . Gradient fractions of 600 l were collected and subjected to immunoblot analysis with polyclonal rabbit antisera against ␣2͞MC3, ␤1i͞LMP2, ␤5i͞LMP7, ␤2i͞MECL-1, PA28␣, PA28␤ (11, 22) , IB␣ (Santa Cruz Biotechnology), or PI31. PI31-specific antisera were raised by immunization of rabbits with purified recombinant GST-PI31 fusion protein following standard procedures.
Metabolic Labeling Experiments. Metabolic labeling of 20S complexes and 20S immunoprecipitation were performed as described (11) .
To analyze viral protein stability, flasks with 2 ϫ 10 6 parental Ad5E1 MEC or -PI31 clone 5 cells were washed with PBS, placed in methionine-free medium for 30 min, and then pulse-labeled with 1 mCi (1 Ci ϭ 37 GBq) [ 35 S]Met. Labeled cells were washed twice with PBS and then chased for 15 min (t:0) plus 1, 2, 3, or 9 h before lysis in 1 ml of 0.5% Nonidet P-40͞0.2% sodiumdeoxycholic acid͞20 mM tri-ethanolamine⅐HCl, pH 8.0͞700 mM NaCl͞with protease inhibitors and 100 g͞ml DNase). Centrifuged detergent lysates were precleared overnight and immu- Immunofluorescence. B8 cells were grown on glass slides and immunofluorescence analysis was performed as described (23) with a Leica TCS-NT Confocal laser scanning microscope. PI31 was detected with affinity-purified rabbit anti-PI31 antiserum and PDI with mouse anti-PDI antibody, clone 1D3 (Stressgene Biotechnologies, Victoria, BC, Canada). Secondary antibodies used were fluorescein-conjugated goat anti-rabbit IgG (Dianova, Hamburg, Germany) and Cy3-conjugated goat antimouse IgG (The Jackson Laboratory).
T Cell Assays. TNF␣-production assays were performed as described (11) . In short, uninfected and infected MEC217 cells cultured without or with tetracyclin (TET) were cocultured with 2 ϫ 10 3 Ad5E1A-specific CTL (24) or 5 ϫ 10 3 Ad5E1B-specific CTL (25) for 9 h or 22 h, respectively, in medium containing 30 units͞ml rec (m)IL-2. TNF␣-secretion was quantified as described (11) , and percentages of specific WEHI cell death were calculated.
LacZ-inducible Ad5-specific T-cell hybridomas (26) were subcloned before usage. To test E1 peptide presentation, 5 ϫ 10 4 hybridoma cells and 1 ϫ 10 5 target cells were cocultured, and induction of LacZ expression was assayed as described (26) . , respectively, with rat monoclonal antibody anti-mouse CD119͞IFN-␥ receptor ␣-chain (PharMingen) or without antibody for 45 min on ice. Cells were washed with PBA and then incubated with FITClabeled goat-anti mouse IgG FAB 2 -fragments (Dianova) or FITC anti-rat IgG2a (PharMingen) for 45 min, washed, and analyzed with a FACScalibur.
Results

PI31 Does Not Inhibit Cellular Proteasome Activity.
In vitro studies have shown that both purified and recombinant PI31 compete with the proteasome regulators PA28 and PA700 for binding to the 20S complex, and that PI31 inhibits 20S enzymatic activity (18) (19) (20) . To explore the effects of this cell-derived proteasome inhibitor in intact cells, we transfected the mouse embryonic cell line Ad5E1 MEC (24), which expresses the adenovirus type 5 early 1 (E1) region and exhibits a low endogenous PI31 expression, with the coding sequences of mouse PI31. Transfectant cells were identified by immunoblot analysis, and five random clones with significantly increased PI31 levels were chosen for further analyses (Fig. 1a) . Overall, PI31 transfectant clones grew remarkably well; the doubling time of the selected five clones (24 h) was identical to that of untransfected Ad5E1 MECs (data not shown). To investigate their growth behavior more precisely, cells were labeled with CFSE and diminution of fluorescence was followed by flow cytometry (Fig. 1b) . No differences in decay of fluorescence signal were detected between parental Ad5E1 MECs and PI31-transfectants, indicating identical growth rates. Because proteasome activity is essential for cell-cycle progression, these findings imply that PI31 has no major impact on the general proteasome function in Ad5E1 cells.
To examine whether the overexpression of PI31 affects other proteasome-mediated processes, Ad5E1 MECs were treated with TNF␣. Degradation of IB␣, which is induced by activation of the NFB-signal transduction pathway and has been shown to be exerted by 26S proteasomes (27) , was analyzed by Western blotting and scan densitometry. Similar decreases in IB␣ levels were observed for Ad5E1 MECs and PI31 transfectants (Fig. 1c) , arguing against an impairment of 26S proteasome function despite high PI31 expression.
Because most nuclear and cytoplasmic proteins are degraded by 26S proteasomes, we investigated further the degradation of the Ad5 E1A and E1B proteins in the presence of PI31. Metabolic labeling and chase analysis revealed comparable degradation rates of the viral proteins between parental and PI31-transfected Ad5E1 MECs (Fig. 1d) . Whereas the two E1A proteins completely diminished within the first 2 h of chase, E1B appeared relatively stable over time, in concordance with the earlier reported long half-life of this protein (28) .
As an alternative approach to monitor PI31 effects on proteasomal proteolysis, we examined degradation of the ubiquitin (Ub)-R-GFP fusion protein, a relatively short-lived N-end-rule substrate (21) , in PI31 transfectant cells. Cells were transiently transfected with a Ub-R-GFP cDNA construct, and R-GFP was accumulated by treatment of the cells with the reversible proteasome inhibitor LLnL (Fig. 1e) . Upon removal of LLnL from the culture medium, GFP signals declined over time, with no discernible differences between parental and PI31 transfectant cells (Fig. 1e) , indicating that protein degradation proceeds normally in the presence of PI31. In addition, no major impact of PI31 on the breakdown of other cellular proteins like c-jun or other viral proteins was detected (data not shown).
It is possible that proteasome redundancy masks potential inhibitory effects of PI31. To test whether stress conditions that lead to increased proteolysis uncover so-far-undetected effects of PI31 on constitutive proteasomes, Ad5 E1 parental and PI31 transfectant cells were subjected to heat shock. Accumulation of polyubiquitin-linked proteins was examined by Western analysis (Fig. 1f ) . These experiments showed that incubation of the cells for 30 min at 42°C (Fig. 1f ) , or up to 3 h at 44 or 45°C (not shown), did not significantly increase the amounts of polyubiquitin-linked proteins in PI31-transfectant cells. Contents of ubiquitinylated proteins remained unchanged during subsequent culture of the cells at 37°C. Thus, PI31-transfectants show no apparent defects in degradation of ubiquitinylated proteins. In contrast, cells treated with the synthetic proteasome inhibitor LLnL did accumulate multiubiquitin conjugates (Fig. 1f ) .
Taken together, these data demonstrate that in contrast to previously obtained in vitro evidence, PI31 does not function as a general inhibitor of proteasome activity in vivo. Cellular PI31 Interferes with Immunoproteasome Maturation. To examine whether PI31 influences the amount of intracellular proteasomes of PA28 or proteasome subunit composition, Ad5E1 parental and transfectant cells were treated with IFN-␥ to induce immunosubunit expression, and total cell lysates were subjected to Western analysis. As shown in Fig. 2a , equal amounts of the proteasomal subunit ␣2͞MC3 were detected in parental and PI31-transfectant cells, which indicates that possible effects of PI31 were not compensated for by an increase in proteasome quantity. Moreover, PI31 did not exert any discernible effects on the quantity of the PA28␣ and PA28␤ subunits. In contrast, a marked increase in the ratios between precursor and mature, N-terminally processed ␤1i͞LMP2 and ␤2i͞ MECL-1 was observed in PI31 transfectants (Fig. 2a) , indicating a reduced or delayed formation of 20S immunoproteasomes in the PI31-transfectant cells. To explore this finding in more detail, precursor and mature 20S complexes of IFN-␥-induced cells were separated by glycerol gradient centrifugation and then analyzed for the presence of immunosubunits. As shown for a representative clone in Fig. 2b , an accumulation of ␤1i͞LMP2-, ␤2i͞MECL-1-, and ␤5i͞LMP7-containing proteasome precursor complexes was detected in PI31 transfectants, indicating that the immunosubunit proforms enter the 16S proteasome precursor Lysates were centrifuged on a glycerol gradient (10 -40%), and collected fractions (600 l) were probed by Western blot analysis with antisera specific for the immunosubunits. Mature and precursor (pr) forms are indicated. Of note, the strong signals obtained for ␤5i͞LMP7 in Ad5E1 MEC fractions are explained by the high affinity of the ␤5i͞LMP7-specific antiserum rather than by protein quantity. (c) MEC-PA28 and -PI31 transfectant cells cultured for 3 days with or without TET in the absence (Upper) or presence (Lower) of IFN-␥ were extracted and probed with antisera specific for PA28␣ and PA28␤ or ␤2i͞MECL-1 and ␤5i͞LMP7. complexes (6) but are inefficiently processed. Although we did not detect any differences in ␤1i͞LMP2 and ␤2i͞MECL-1 mRNA levels between Ad5E1 MECs and PI31-transfectant clones (data not shown), we infer that PI31 directly interferes with the maturation of immunoproteasomes.
As PA28 was suggested to enhance immunoproteasome formation (29) , one could speculate that the negative effects of PI31 on immunoproteasome assembly result from competitive inhibition of PA28 binding. However, analysis of a PI31-transfected MEC clone with TET-regulated PA28 expression (Figs. 1a and 2c Upper) showed that PI31 impairs immunosubunit incorporation (Fig. 2c Lower) even in the presence of large quantities of PA28 (lanes 2 and 4). From these data and the results of Murata et al. (30) showing that the absence of PA28 does not affect immunoproteasome assembly, we infer that PI31 is unlikely to exert its effects by competing with PA28 for 20S binding.
To confirm our finding that PI31 diminishes immunoproteasome maturation, we transfected MEC217 cells (11) that upregulate immunosubunit expression in response to removal of TET from the culture medium with PI31. Parental MEC217 and a PI31 transfectant clone (Fig. 1a) , cultured without TET, were metabolically labeled. Cell lysates were fractionated on glycerol gradients, and proteasomes were immunoprecipitated. Analysis of the 16S precursor fractions (Fig. 3 Upper) revealed that both MEC217 and PI31-transfectant cells incorporated the immunosubunit proforms in their proteasome precursor complexes. Proforms of ␤1͞␦, ␤2͞MC14, and ␤5͞MB1 were not detected, indicating that at most a minor fraction of precursor complexes contained the constitutive catalytic subunits. However, whereas the immunoproteasome precursors matured into 20S immunoproteasomes in MEC217 cells (Fig. 3 Lower) , only approximate ratios of 1:1 between constitutive subunits and immunosubunits were reached in 20S proteasomes of MEC217-PI31 cells. Thus, PI31 allows the formation of 16S immunoproteasome precursor complexes but severely impairs their maturation to functional 20S complexes, as is evident from the preservation of constitutive ␤1͞␦, ␤2͞MC14, and ␤5͞MB1 in 20S proteasomes of MEC217-PI31.
PI31 Localizes at the Nuclear Envelope͞Endoplasmic Reticulum (ER)
Membrane. To investigate whether PI31 is scattered throughout cells or confined to specific subcellular compartments, we analyzed the intracellular localization of PI31 by immunofluorescence microscopy. Cells grown on micro-slides were stained with anti-PI31 antiserum and FITC-labeled secondary antibody. Confocal microscopic analysis (Fig. 4) showed an unequal distribution of PI31 throughout cells, with a predominant localization at the cytosolic site of the nuclear envelope͞ER membrane. Colocalization studies with the ER markers PDI (Fig. 4) , calnexin, and gp96 (not shown) confirmed this presumed localization. Interestingly, immunoproteasomes also have been described to reside at the nuclear envelope͞ER membrane (31) , making this the most likely location for immunoproteasomes to assemble and mature. Therefore, our results suggest that the intracellular localization of PI31 is in agreement with the observed effects of this molecule on immunoproteasome precursor maturation.
PI31 Diminishes Processing of an Immunoproteasome-Dependent CTL
Epitope. The Ad5E1 proteins contain two antigenic peptides, E1A 234-243 (24) and E1B 192-200 (25) , that are presented by H2-D b MHC-I molecules and are important targets for Ad5-specific murine CTL. We recently showed (11) that infected cells processed E1B 192-200 efficiently only when the IFN-␥-inducible proteasome immunosubunits were expressed. In contrast, the liberation of E1A 234-243 requires proteasome activity (not shown) but occurs independently of the presence of immunoproteasomes. As shown in Fig. 5a , TET-regulated expression of the immunosubunits in Ad5-infected MEC217 cells does not influence the presentation of E1A 234-243 to specific CTL, whereas immunosubunits enhance the presentation of the E1B 192-200 epitope, as reported (11) .
To investigate whether PI31-inhibition of IFN-␥-induced immunoproteasome formation has functional consequences, we analyzed antigen processing of the two Ad5 CTL epitopes in Fig. 3 . MEC217 and MEC217-PI31 cells were cultured in the absence of TET for 1 day to induce immunosubunit expression and then labeled for 4 h with [ 35 S]Met and extracted. Detergent lysates were centrifuged on glycerol gradients (10 -40%) and collected as 600-l fractions. Proteasome complexes were immunoprecipitated from the fractions, separated by NEPHGE-SDS͞ PAGE two-dimensional gel electrophoresis, and visualized by autoradiography; the subunits were assigned according to Elenich et al. (35) . (26) . Whereas untreated MECs were not recognized above background levels (because of low MHC class I expression; see Fig. 6a ), all IFN-␥-treated cells exhibited a similar ability to stimulate E1A-specific hybridoma cells (Fig. 5b) . In contrast, E1B 192-200 was recognized on IFN-␥-treated parental Ad5E1 MECs (Fig. 5b) , but none of the PI31 transfectant clones was able to stimulate E1B-specific hybridoma cells (Fig. 5b) . Thus, PI31 does not affect E1A 234-243 presentation, but interferes with antigen processing of the immunoproteasome-dependent E1B CTL epitope.
One explanation of the above results could be that PI31 also acts as a transcription or translation inhibitor. However, Northern analysis revealed no differences in mRNA levels of E1B and H2-D b heavy chain (HC) between IFN-␥-treated Ad5E1 MECs and derived transfectants (not shown). Also, levels of E1B protein synthesis are similar in parental and transfectant cells (Fig. 1d) , and PI31-transfected cells up-regulated the TAP2 protein after IFN-␥-stimulation, indicating that the IFN-␥-signaling pathway is functional in the presence of excessive amounts of PI31 (not shown). Taken together, our results imply that diminished presentation of the immunoproteasomedependent E1B 192-200 on PI31-Ad5E1 MECs is most likely the result of reduced generation of this antigenic peptide in the absence of 20S immunoproteasomes. Fig. 6b and data not shown) . Therefore, we infer that defective immunoproteasome maturation in PI31 transfectant cells leads to insufficient production of class I ligands which impairs the IFN-␥-induced up-regulation of MHC class I cell-surface expression.
Discussion
Our experiments show that, in contrast to the observed inhibitory effects of PI31 on purified 20S complexes in vitro, PI31 does not inhibit the general 20S͞26S proteasome activity in intact cells. Instead, we found that PI31 specifically interferes with 20S immunoproteasome formation and, in parallel, with MHC class I-presentation of immunoproteasome-dependent CTL epitopes. The formation of 20S constitutive proteasomes seems unaffected. Remarkably, the inhibitory effects of PI31 occur at the level of proteasome precursor-complex processing and become apparent only upon analysis of the mature 20S proteasome population. Thus, unprocessed proforms of ␤1i͞LMP2, ␤5i͞ LMP7, and ␤2i͞MECL-1 enter the proteasome precursor in PI31-expressing cells, but only a small percentage of immunosubunit-containing precursor complexes reaches the mature stage (Figs. 2b and 3) . Nevertheless, the total cellular proteasome contents are not detectably altered under conditions of PI31 overexpression, implying that PI31 selectively hinders immunoproteasome maturation.
Prosequence removal, leading to proteasome activation, takes place in the 16S precursor complex and is a multistep process (5) in which the N-terminal sequences are removed by autocatalytic cleavages (6) . Our finding that immunoproteasome precursor complexes are assembled but fail to mature properly in PI31-transfectant cells implies that PI31 specifically interferes with the processing of immunosubunit prosequences. Therefore, our present data suggest that, rather than inhibiting 20͞26S proteasome activity as such, intracellular PI31 interferes with the autocatalytic steps that result in the formation of active 20S immunoproteasomes.
In parallel to impaired immunoproteasome formation, IFN-␥-treated PI31 2ϩ cells exhibit a severely reduced MHC class I presentation of the immunoproteasome-dependent E1B CTL epitope (Fig. 5b) . In contrast, MHC class I antigen processing of the immunoproteasome-independent E1A 234-342 epitope, which is presented by the same MHC class I molecule, is not impaired in these cells (Fig. 5b) , indicating the intact functioning of the non-proteasome-related components of the antigen processing pathway, and that the amount of class I molecules available for peptide binding is not limiting. Instead, the reduced up-regulation of both H2-D b and H2-K b cell-surface expression after IFN-␥ stimulation (Fig. 6 and Table 1) suggests that generation of a large number of CTL epitopes is inhibited in PI31-transfected cells, resulting in insufficient amounts of antigenic peptides to load newly synthesized MHC class I molecules. This observation was unexpected, because we found previously that immunosubunit introduction into MECs does not alter MHC class I cell-surface expression (unpublished observations). On the other hand, both down-regulation of ␤1i͞LMP2 expression in lymphoma T cells and the disruption of ␤5i͞LMP7 expression in mice were shown to diminish the MHC class I cell-surface levels (32, 33) . Taken together, and in agreement with other reports, these findings imply that, in cells with high MHC class I expression levels, MHC class I assembly is limited by peptide availability. Moreover, because MHC class I cellsurface expression is down-regulated upon inhibition of immunoproteasome formation, we infer that immunosubunit incorporation increases the yield of antigenic peptides. In agreement with our findings, a previous study (34) also suggested that MHC class I loading in IFN-␥-induced cells requires full immunoproteasome activity.
As both PI31 and immunoproteasomes (or their precursors) localize at the ER membrane (31), we speculate that PI31 may serve to control immunoproteasome formation and may thereby maintain an intracellular balance between constitutive and immunoproteasomes. Whereas proteasome components that play a central role in cellular metabolism are highly conserved between yeast and mammals, these components of the proteasome system that are involved in MHC class I antigen processing are found in mammals only. Interestingly, like PA28 and the immunosubunits, PI31 also has no homologue in yeast, which may be indicative of a specific function of this molecule in the antigen-processing pathway. Interestingly, many cell types, for example, fibroblasts, display a low constitutive expression of the proteasome immunosubunits. Therefore, we suggest that PI31 plays a regulatory role by preventing the formation of immunoproteasomes in the absence of infection.
